Group 3 Pulmonary Hypertension: Mechanistic Insights, Clinical Challenges, and Evolving Therapies
Steven C. Liu, Madeline Ku, Priyanka Mohnani, Tanvi Borse, Bharat Bajantri · 2026
Read Group 3 Pulmonary Hypertension: Mechanistic Insights, Clinical Challenges, and Evolving Therapies by Steven C. Liu, Madeline Ku, Priyanka Mohnani, Tanvi Borse, Bharat Bajantri (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13566783.txt.
Description
Steven Liu and co-authors review high lung pressure that stems from chronic lung disease and low oxygen, in a 2026 paper. This form, classed as group three, strains the right side of the heart and cuts life short. It was once seen as a mere side effect of lung damage.
The review now treats it as a disorder in its own right, with vessel reshaping and faulty signals at its core. The authors cover how it is found and judged, and why past drug trials mostly failed. New lung targeted methods aim to help vessels while sparing air exchange. They call for finer patient sorting and fresh therapies.
Catalog record
| CREATOR | Steven C. Liu, Madeline Ku, Priyanka Mohnani, Tanvi Borse, Bharat Bajantri |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |